Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMU-838 in progressive multiple sclerosis
NL-OMON60733Phase 2Not yet recruiting
- Sponsor
- Immunic Therapeutics
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vidofludimus calcium in multiple sclerosis (MS), secondary-progressive multiple sclerosis (SPMS), primary progressive multiple sclerosis (PPMS), sponsored by Immunic Therapeutics. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
vidofludimus calcium
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NL-OMON60733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60733.